AUSAF (Australis Capital) Return-on-Tangible-Equity: -71.95% (As of Dec. 2021)


What is Australis Capital Return-on-Tangible-Equity?

Australis Capital AUSAF -95.00% Return-on-Tangible-Equity is -71.95% as of Dec. 2021.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Australis Capital's annualized net income for the quarter that ended in Dec. 2021 was $-14.74 Mil. Australis Capital's average shareholder tangible equity for the quarter that ended in Dec. 2021 was $20.48 Mil. Therefore, Australis Capital's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2021 was -71.95%.

The historical rank and industry rank for Australis Capital's Return-on-Tangible-Equity or its related term are showing as below:

AUSAF's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.88
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Australis Capital  (OTCPK:AUSAF) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Australis Capital Return-on-Tangible-Equity Related Terms


Australis Capital Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Australis Capital's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australis Capital Return-on-Tangible-Equity Chart

Australis Capital Annual Data
Trend Mar18 Mar19 Mar20 Mar21
Return-on-Tangible-Equity
0.00 -14.77 -45.98 -71.98

Australis Capital Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -273.64 48.55 -127.38 -60.29 -71.95

AUSAF vs ZTS, CTLT, VTRS: Return-on-Tangible-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Australis Capital Return-on-Tangible-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Australis Capital's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Australis Capital's Return-on-Tangible-Equity falls into.



Australis Capital Return-on-Tangible-Equity Calculation

Australis Capital's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2021 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2021 )  (A: Mar. 2020 )(A: Mar. 2021 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2021 )  (A: Mar. 2020 )(A: Mar. 2021 )
=-20.098/( (30.374+25.473 )/ 2 )
=-20.098/27.9235
=-71.98 %

Australis Capital's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2021 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2021 )  (Q: Sep. 2021 )(Q: Dec. 2021 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2021 )  (Q: Sep. 2021 )(Q: Dec. 2021 )
=-14.736/( (20.752+20.208)/ 2 )
=-14.736/20.48
=-71.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2021) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of -71.95% mean?
Australis Capital (AUSAF) has a Return-on-Tangible-Equity of -71.95% as of Dec. 2021. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Australis Capital and its competitors.
Is Australis Capital's Return-on-Tangible-Equity too high?
Australis Capital's current Return-on-Tangible-Equity is -71.95%.
How does Australis Capital's Return-on-Tangible-Equity compare to ZTS and CTLT?
Australis Capital's Return-on-Tangible-Equity of -71.95% can be compared against companies in the Drug Manufacturers industry. The industry median Return-on-Tangible-Equity is 7.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Australis Capital and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australis Capital's current Return-on-Tangible-Equity is -71.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australis Capital stock overvalued right now?
Australis Capital (AUSAF) has a current Return-on-Tangible-Equity of -71.95%. The current Return-on-Tangible-Equity is -71.95%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Australis Capital (AUSAF), the current Return-on-Tangible-Equity is -71.95% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Australis Capital Business Description

Address 376 E. Warm Springs Road, Suite 190, Las Vegas, NV, USA, 89119
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.